Jounce Therapeutics, Inc. (JNCE)
(Delayed Data from NSDQ)
$5.79 USD
+0.42 (7.82%)
Updated May 3, 2019 04:00 PM ET
After-Market: $5.78 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JNCE 5.79 +0.42(7.82%)
Will JNCE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JNCE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNCE
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
JNCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Stocks to Buy as the Drug Industry Rebounds in 2023
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences